To assess the efficacy, tolerability and safety of vitamin K2-7 in patients with peripheral neuropathy (PN). This study was conducted in 100 patients with PN suffering from VBD or T2DM. Vitamin K2-7 capsules (200 mcg) were given orally for 8 wk followed up to the 12th week. Symptoms included tingling and numbness along with weakness, fatigue, and cramps. The intensity of the symptoms of PN was assessed on a Visual Analog Scale (VAS). At baseline, the VAS score was 6-9 for VBD group and 8-10 for T2DM group. After treatment with Vitamin K2-7 by the 12th week, VAS score had reduced to 1-2 in both groups. The decrease was statistically significant (P < 0.0001). For the first time, in larger sample size, it has been shown that Vitamin K2-7, 200 mcg for 8 wk, has a therapeutic activity for the symptoms of PN in VBD and T2DM. The reduction in symptoms was persistent in spite of de-challenge of Vitamin K2-7. Vitamin K2-7 was also well tolerated by all the patients. Thus, it can be concluded that Vitamin K2-7 has potential therapeutic effects for PN due to VBD or T2DM.